Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Relacorilant Exposure in Healthy Subjects
NCT03512548Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of relacorilant in Cushing's syndrome (5 arms), sponsored by Corcept Therapeutics. Primary endpoint: Area under plasma concentration-time curve up to the last quantifiable sample. Started Apr 2018; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT03512548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512548.